China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
|
CN |
|
Libas Consumer Products Ltd
NSE:LIBAS
|
IN |
|
A
|
Atalaya Mining PLC
LSE:ATYM
|
CY |
Wall Street
Price Targets
Price Targets Summary
China Resources Double-Crane Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 25.83 CNY with a low forecast of 25.25 CNY and a high forecast of 26.93 CNY.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is China Resources Double-Crane Pharmaceutical Co Ltd's stock price target?
Price Target
25.83
CNY
According to Wall Street analysts, the average 1-year price target for China Resources Double-Crane Pharmaceutical Co Ltd is 25.83 CNY with a low forecast of 25.25 CNY and a high forecast of 26.93 CNY.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
4%
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's revenue is 4%. The projected CAGR for the next 4 years is 4%.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Operating Income forecast?
Projected CAGR
17%
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's operating income is 8%. The projected CAGR for the next 2 years is 17%.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Net Income forecast?
Projected CAGR
8%
For the last 13 years the compound annual growth rate for China Resources Double-Crane Pharmaceutical Co Ltd's net income is 9%. The projected CAGR for the next 3 years is 8%.
